CONTENTS

        Chapters
  1. Research and Regulatory Approval
  2. Use of Injectables
  3. Effectiveness and Reversibility
  4. Side Effects and Complications
  5. More Evidence in the Cancer Debate
  6. Noncontraceptive Health Benefits
  7. Counseling Issues
  8. Communicating with the Public
  9. Maximizing Access and Quality

Published with this issue:

HIGHLIGHTS


Published by the Population Information Program, Center for Communication Programs, The Johns Hopkins School of Public Health, 111 Market Place, Suite 310, Baltimore, Maryland 21202-4012, USA

Volume XXIII, Number 2 August 1995

Infection Prevention

Increasing use of injectables challenges programs to prevent transmission of the AIDS-causing human immunodeficiency virus (HIV), hepatitis B, and other blood-borne infections to clients, clinic staff, and the public through contaminated needles and syringes. Injections for contraception are a small proportion of the total number of injections given, which include immunizations, vitamins, antibiotics, and others. Thus any risk from contraceptive injections is a very small part of a large problem. For example, the WHO Expanded Program on Immunization (EPI) estimates that children under five receive over 5.5 billion injections of all types each year, and about half of these injections risk infection of some sort (345).

Training must address common mistakes that providers make—for example, giving several clients injections with the same needle and syringe without sterilizing or disinfecting the equipment (see sidebar, Five Basic Steps of Infection Prevention: Do's and Don'ts). EPI has estimated the risk of infection if all providers reused each needle and syringe one time for immunizations without sterilizing or disinfecting them. (EPI recommends that infants and women of childbearing age each receive five immunizations.) In areas such as sub-Saharan Africa, where the prevalence of hepatitis B is about 10%, 260 per 100,000 fully immunized infants would be infected with hepatitis B. In areas with an intermediate prevalence of HIV infection of 1% among pregnant women, three infants and 12 women per 100,000 would be infected with HIV (16).

Both donors and family planning clients prefer disposable needles and syringes to reusable equipment. Clients may be reassured when providers use a new needle and syringe for an injection. In Kenya, for example, family planning clients feared that some providers were reusing needles and syringes without sterilizing them. In response, the Family Planning Association of Kenya (FPAK) sells disposable needles and syringes to clients, who then hand them to the FPAK provider giving the injection (144).

The choice of reusable or disposable equipment may depend on cost. EPI estimates that at low volume—five injections per day, for example—costs are about equal. As volume increases, reusable equipment becomes cheaper. In clinics giving 50 injections per day, for example, disposable equipment costs $0.05 per injection and reusable equipment, $0.01 per injection. In addition to the workload, costs depend on procurement costs, the cost of fuel for sterilization and disposal, and the lifespan of the equipment (344). USAID and UNFPA, which provide supplies free of charge, ship injectables with disposable equipment (55, 118).

Infections may be transmitted through improper storage of vials containing several doses of injectable. For example, clinics operating once a week may store partially used vials for one or two weeks. To avoid this problem, use of one-dose vials is recommended.

Both motivation and supervision are essential to infection prevention. Understanding their own risk of infection and the risk to clients can motivate providers to follow safe procedures. In one study of immunizations, for example, providers suffered one needlestick for every 500 injections (294). If stuck with a needle used on a client infected with hepatitis B, 5% to 27% of providers become infected (96). Also, supervisors need to ensure a steady supply of equipment, enforce procedures for infection prevention, and account for disposable equipment after its use (305).


Previous | Next
Top of Page | Table of Contents


111 Market Place, Suite 310, Baltimore, MD 21202, USA
Phone: (410) 659.6300/Fax: (410) 659.6266/E-mail: Poprepts@jhuccp.org

Population Reports